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Abstract: Tenofovir is a widely used antiretroviral medication indicated to treat adults and 
children infected with HIV. Current guidelines for the management of HIV infection recommend 
tenofovir disoproxil fumarate (TDF) as a component of the preferred first-line combination 
antiretroviral therapy. The efficacy, tolerability, prolonged half-life allowing for once-daily 
administration, and availability as a component of several fixed-dose formulations make TDF 
an attractive choice for treatment-naive and treatment-experienced HIV-infected patients. TDF 
is also widely used as a component of postexposure prophylaxis in noninfected individuals. 
Most importantly, it has been recently approved for use as pre-exposure prophylaxis for non-
infected adults and adolescents to reduce the risk of HIV transmission. With increasing use of 
TDF among adults and children, understanding of the potential for drug-associated side effects 
is important. This review focuses on the neuropsychiatric effects of tenofovir in adults and 
children with HIV infection in comparison with other antiretroviral drugs.
Keywords: HIV, tenofovir, neuropsychiatric effects
Introduction
Antiretroviral therapy (ART) has transformed the landscape of HIV medicine. Since 
the introduction of combination ART (cART) in the mid-nineties, the morbidity and 
mortality of patients with HIV infection has decreased dramatically.1,2 Combination 
of three or more antiretroviral (ARV) medications is required to achieve and main-
tain control of viral replication.1 Currently, over 25 individual ARV medications are 
approved by the Food and Drug Administration (FDA) to treat HIV-infected patients 
in the United States. Knowledge about efficacy and toxicity of ARV drugs is crucial 
in designing the most potent, tolerable, and convenient ART to optimize outcome of 
HIV therapy.
Since its introduction, tenofovir (TFV) disoproxil fumarate (DF) has become an 
important component of cART in adolescents and adults. Tenofovir disoproxil fumarate 
(TDF) was approved by the US FDA for the treatment of HIV-1 infection in 2001 for 
adults and children older than 12 years of age. In January 2012, TDF was approved 
by the FDA for use in pediatric patients . 2 years of age and in July of 2012, the TDF 
coformulation with emtricitabine (FTC), Truvada (Gilead Sciences, Foster City, CA, 
USA), became the first drug approved by the FDA for use in noninfected adolescents 
and adults to reduce the risk of sexually acquired HIV infection as part of pre-exposure 
prophylaxis (PrEP).
Several clinical trials have demonstrated high efficacy of TDF in suppressing viral 
replication in both treatment-naive and treatment-experienced adult, adolescent, and 
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pediatric patients.3,4 TDF has higher antiviral potency com-
pared with other nucleoside reverse-transcriptase inhibitors 
(NRTIs) with the median decrease in plasma HIV RNA in 
subjects receiving TDF, zidovudine (AZT), or stavudine 
(d4T) monotherapy being 1.4, 0.5, and 0.5 log
10
,  respectively.5 
Pediatric studies have equally demonstrated excellent viro-
logic response to TDF.6–8 Due to its efficacy, safety profile, 
and tolerability, TDF has been chosen as a component of 
preferred ART recommended as initial HIV treatment by 
the Department of Health and Human Services (DHHS) 
and the World Health Organization (WHO) guidelines for 
antiretroviral-naive adults and children (Table 1).9–11
Additionally, in 2011 the HPTN 052 trial conducted by 
the HIV Prevention Trials Network in the US, showed that 
use of a TDF-containing regimen in an HIV-positive partner 
resulted in a 96% reduction in transmission risk.12 This study 
formed the basis for the concept of treatment as prevention, 
which has subsequently led to several studies investigating 
the safety and efficacy of using a TDF-containing regimen 
in noninfected individuals for PrEP.
With increasing use of TDF among adults and children, 
understanding of the potential for drug-associated side effects 
is important. This article will review the neuropsychiatric 
effects of TDF in comparison with other ARV drugs.
Tenofovir in clinical practice
Classified as an nucleotide reverse-transcriptase inhibitor 
(NtRTI), TDF is a prodrug that is converted to TFV, an 
acyclic nucleoside phosphonate (nucleotide) analogue of 
adenosine 5′-monophosphate with activity against HIV-1, 
HIV-2, and hepatitis B.13–15 TDF prevents HIV replication 
by competitively inhibiting the enzyme reverse tran-
scriptase and resulting in DNA chain termination in active 
and resting lymphoid cells and macrophages.15
TDF is formulated as a tablet in strengths of 150, 200, 
250, and 300 mg. Recently, a powder formulation has 
become available for oral administration in children. TDF 
has been coformulated with several other ARV medications. 
Truvada (Gilead Sciences) consists of TDF and another NRTI 
FTC. Atripla (Gilead Sciences and Bristol-Myers Squibb, 
New York, NY, USA) is a fixed-dose coformulation (FDC) 
of  TDF with FTC and the first-generation non-nucleoside 
reverse-transcriptase inhibitor (NNRTI) efavirenz (EFV). 
The newest FDA-approved TDF containing coformulation 
is Complera (Gilead Sciences), which consists of TDF, FTC, 
and the second-generation NNRTI rilpivirine (RPV). All 
coformulations of TDF are especially attractive in clinical 
practice because they allow for once-daily administration 
of multiple drugs in a single pill, thus decreasing overall 
pill burden and creating a better setting for maintaining 
long-term adherence.
Due to low pill burden, availability in FDC, affordable cost, 
and storage, TDF is increasingly prescribed as a component of 
the ARV regimens used for the prevention of HIV transmis-
sion, including prevention of mother-to-child transmission 
and PrEP and postexposure prophylaxis (PEP) in noninfected 
adolescents and adults.16–18 In the Pediatric HIV/AIDS Cohort 
Study (PHACS), TDF use in HIV-infected women during 
pregnancy has been reported to have doubled in the last 5 
years, with over 40% of pregnant mothers in the large study 
cohort receiving TDF.19 Recent studies (CAPRISA004, iPrEX, 
TDF2, Partners for PrEP) have investigated the use of TDF 
in noninfected adults for PreP of HIV infection primarily 
through sexual contact.20–24 In the CAPRISA004 study, the 
use of 1% TFV gel by noninfected women with high risk for 
HIV exposure reduced risk of HIV acquisition by 39%.21 The 
studies of oral TDF/FTC (iPREX and TDF2) reported 44% and 
62% efficacy in preventing HIV transmission, respectively.22,23 
The study Partners for Prep demonstrated 63% reduction in 
HIV transmission in adults using mono-prophylaxis with oral 
TDF.24 Despite some contradicting results on low efficacy of 
oral TDF/FTC and TFV vaginal gel in two other studies (FEM-
Prep and VOICE),25,26 the evidence from studies demonstrating 
the efficacy of PreP was considered sufficient by the FDA to 
approve the TDF-based FDC Truvada (Gilead Sciences) for 
use as PrEP in noninfected individuals in July 2012. With this 
new approval, the use of TDF in noninfected adolescents and 
adults is likely to increase significantly in the near future.
Table 1 Summary of the DHHS and WHO adult and pediatric 
HIV treatment guideline recommendations9–11
2012 DHHS US preferred regimens for antiretroviral-naive adult patients
•  Efavirenz/tenofovir/emtricitabine
•  Ritonavir-boosted atazanavir + tenofovir/emtricitabine
•  Ritonavir-boosted darunavir + tenofovir/emtricitabine
•  Raltegravir + tenofovir/emtricitabine
2010 WHO preferred regimens for antiretroviral-naive adult patients
•  Zidovudine + lamivudine + efavirenz
•  Zidovudine + lamivudine + nevirapine
•  Tenofovir + (lamivudine or emtricitabine) + efavirenz
•  Tenofovir + (lamivudine or emtricitabine) + nevirapine
2011 DHHS preferred regimens for 2-NRTI backbone for antiretroviral-
naive pediatric patients (for use with additional antiretroviral drugs)
•  Abacavir + (lamivudine or emtricitabine) (children age $ 3 months)
•  Tenofovir + (lamivudine or emtricitabine) (adolescents age $ 12 years 
and Tanner stage 4 or 5 only)
•  Zidovudine + (lamivudine or emtricitabine)
Abbreviations: DHHS, Department of Health and Human Services; WHO, World 
Health Organization; NRTI, nucleoside reverse-transcriptase inhibitor.
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Pharmacokinetics and toxicity  
of TDF
TFV has a long half-life of approximately 17 hours, which 
allows for convenient once-daily dosing.27,28 TFV is water-
soluble, and its oral bioavailability in fasted subjects is 
approximately 25%. High-fat meals increase bioavailability 
to 39% compared to light meals without significant effect.29 
Unchanged TFV is excreted by the kidneys through a com-
bination of glomerular filtration and active tubular secretion. 
Renal impairment (creatinine clearance , 50 mL/minute) 
requires reduction of TDF dosing with extended dosing 
intervals.29 Since TFV has minimal involvement with hepatic 
metabolism, no dose adjustment is required for patients with 
hepatic impairment or coinfection with hepatitis.
TFV is not involved with cytochrome (CYP) 
P450 metabolism, resulting in fewer drug–drug interac-
tions than other ARV drugs, such as protease inhibitors 
(PIs). This lack of significant drug–drug interactions is par-
ticularly beneficial for HIV-infected patients who may have 
comorbidities requiring other medications. TDF, however, 
does have significant interaction with the NRTI didanosine 
(ddI). Coadministration of TDF and ddI results in increased 
ddI plasma concentrations and toxicity. DHHS guidelines 
recommend avoiding coadministration of these ARV drugs. 
If coadministration is required, ddI dose reduction is recom-
mended with close monitoring for ddI-associated toxicity, 
such as pancreatitis and peripheral neuropathy.9,11
Two important drug-related toxicities – renal and bone 
toxicity – have been associated with TDF use in children 
and adults. Rare cases of acute renal failure and Fanconi 
syndrome (dysfunction of renal tubules resulting in exces-
sive renal loss of glucose, amino acids, and electrolytes) have 
been described in association with TDF exposure.30–33 The 
cumulative incidence of nephrotoxicity in TDF-containing 
regimens has been reported between 1% and 4%, with the rate 
of Fanconi syndrome between 0.5% to 2.0%.34  Nephrotoxicity 
most frequently occurs in patients with prior underlying 
renal abnormalities or those concomitantly exposed to other 
nephrotoxic agents. In clinical trials and practice, however, 
serious renal impairment associated with TDF has rarely 
been reported.35 The mechanism for renal toxicity is not well 
understood, but may involve adverse effects on transporter 
proteins in the kidney tubules.36 Following discontinuation 
of TDF, associated renal toxicity usually resolves without 
consequences.37 Current drug-manufacturer and treatment 
recommendations include assessing creatinine clearance 
prior to initiation and throughout the length of therapy with 
TDF, avoiding administration of TDF concurrently with other 
nephrotoxic drugs, and continued monitoring of renal func-
tion while on a TDF-containing regimen.9,11,29
A decrease in bone mineral density (BMD) has also 
been observed in HIV-infected adult and pediatric patients 
treated with TDF-containing regimens, with dual X-ray 
absorptiometry demonstrating small decreases in spine and 
hip BMD. The reported decrease in BMD, however, does not 
appear to be clinically relevant in adult patients, except for the 
rare cases of osteomalacia reported with TDF use.29,38,39 Poten-
tial decreases in BMD are concerning for prepubertal children 
or adolescents in early stages of pubertal development. Studies 
have indicated that younger children (Tanner stages 1 and 2 of 
sexual maturation) may be at higher risk for TDF-associated 
decreases in BMD than older patients with more advanced 
stages of sexual development (Tanner stage $ 3).11
Unlike other NRTIs, such as AZT and d4T, which have 
been linked to significant mitochondrial damage, TDF has been 
associated with minimal mitochondrial toxicity. Adverse effects, 
such as lipoatrophy, lactic acidosis, or peripheral neuropathy, 
are typically not related to TDF use.40 Nevertheless, rare cases 
of lactic acidosis and severe hepatomegaly with steatosis have 
been reported in patients treated with TDF, and discontinuation 
of TDF is recommended in any patient exhibiting clinical or 
laboratory findings suggestive of these side effects.29
Neuropsychiatric complications  
of HIV and ART
Neuropsychiatric disease in HIV-infected patients may be 
caused by HIV infection itself, toxicity from ART, a preexist-
ing underlying neuropsychiatric condition nonrelated to HIV, 
opportunistic comorbidities resulting from HIV-associated 
immunosuppression, or a combination of several of these 
conditions. Primary central nervous system (CNS) lym-
phoma and progressive multifocal leukoencephalopathy are 
associated with profound immune suppression.  Additionally, 
opportunistic infections affecting the CNS, such as crypto-
coccosis and toxoplasmosis, may cause neurological mani-
festations in severely immunocompromised HIV-infected 
patients.  Moreover, history of substance abuse, head injury, 
cerebral vascular accident, or aging can also contribute to the 
development of neuropsychiatric impairment in HIV-infected 
patients.41 Distinguishing the etiology of neuropsychiatric 
manifestations in HIV-infected patients in order to ensure the 
most optimal therapeutic approach is crucially important.
Neuropsychiatric effects of HIV
The direct effect of HIV infection on the CNS has been asso-
ciated with the development of asymptomatic  neurocognitive 
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impairment, HIV-associated neurocognitive disorder 
(HAND), and HIV-associated dementia (HAD), or AIDS 
dementia complex. HAD is the most severe neuropsychiatric 
manifestation of HIV. It is a clinical syndrome of severe 
cognitive, motor, and behavioral dysfunction that usually 
develops in patients with untreated HIV infection.42 HAND 
is considered to be less severe than HAD, with symptoms 
including impaired memory, attention, processing speed, 
and executive functioning; speech, language, visuospatial 
deficits; and slowing of psychomotor processing and motor 
speed.43
HIV penetrates the CNS soon after infection via infected 
immune cells, such as CD4+ T lymphocytes, dendritic cells, 
monocytes, and macrophages. As a major target of HIV, the 
CNS continues to be affected by the virus throughout the 
course of the disease.44 Subtype-D HIV has been implicated 
in being more neurovirulent than other subtypes in adults.45 
Cognitive impairment frequently develops secondary to 
chronic inflammation, resulting in neurodegeneration.46 The 
level of HIV viremia (HIV RNA) in cerebrospinal fluid (CSF) 
has been shown to correlate with severity of HIV-associated 
dementia and neuropsychological test performance. Elevated 
HIV RNA in CSF can predict the development of subsequent 
neurocognitive impairments.47–51 Following the introduction 
and effective application of ART in clinical settings, a pro-
found reduction in the incidence and severity of HAD, as well 
as major CNS opportunistic infections, has been observed.43 
The dramatic decrease in incidence of HAD from .50% to 
2%–8% has been suggested to be mediated by suppression 
of HIV replication and reduction in circulating lipopolysac-
charide, both preventing compromise of the blood–brain 
barrier and migration of HIV-infected monocytes from 
systemic circulation into the brain.52,53 A multicenter study 
of HIV-infected older children (7–16 years of age) in the US 
and Puerto Rico demonstrated that neurocognitive deficits 
acquired in early childhood were reversible with consistent 
use of ART in pediatric patients with HIV infection.54 As a 
component of cART therapy, TFV has contributed to the 
decrease in severe neuropsychiatric manifestations of HIV 
disease.
Although clear evidence supports the success of cART 
in prevention of the severe neuropsychiatric disease asso-
ciated with HIV, the prevalence of minor HIV-associated 
cognitive impairment appears not to be affected by cART 
and has been noted to be on the rise in recent years.55,56 This 
effect can be partially due to improved survival and longev-
ity of the patients with HIV infection with modern, highly 
effective cART. Cohort studies have described a prevalence 
of  demonstrable cognitive impairments in 30%–60% of 
HIV-infected adults.44 Not surprisingly, the history of low 
nadir in CD4+ cell count below 50 cells/mm3 was linked to a 
greater risk of neurocognitive impairment.56 Similar to adults, 
children with history of severe immunosuppression were also 
more likely to have residual neurocognitive deficits.56 The 
constant presence of low levels of HIV in the CNS along 
with the associated immune activation and ongoing inflam-
mation may be related to more subtle forms of brain injury, 
which has become a focus of clinical attention and research 
in the cART era.44
HAND and neurocognitive impairment continue to be 
diagnosed even among HIV-infected patients with immune 
recovery on cART.53,57,58 The presence of HAND in patients 
effectively treated with ARVs may be caused by limited 
penetration and distribution of ARV drugs in the CNS.46 The 
normal function of the blood–brain and blood–CSF barriers 
is to shield the brain from harmful, toxic substances and 
provide a precisely regulated environment in the CNS. The 
CNS acts as a sanctuary site for HIV, and HIV replication 
can persist despite virologic suppression in blood and other 
tissues.59 This ongoing low-level viral replication within the 
CNS may lead to neuronal damage, resulting in long-term 
cognitive impairment.
Minor HIV-associated cognitive impairment may also be 
caused by the insurgence of drug-resistant HIV in the CNS 
while on cART.60 By limiting CNS penetration of ARV drugs, 
the blood–brain/blood–CSF barrier potentially decreases 
CNS toxicity of ARV medications, but also contributes to 
continued presence of HIV in the CNS despite an undetect-
able HIV RNA viral load in the peripheral blood stream. 
Hindering the penetration of ARV drugs into the CNS can 
therefore result in subtherapeutic ARV drug concentrations, 
resulting in the development of drug resistance and ongoing 
replication of the HIV within CNS. Ultimately, this may 
contribute to treatment failure and persistent neurocognitive 
deficits, even in the presence of effective cART.46
Neuropsychiatric effects of ART
Continued presence of minor cognitive impairment in HIV-
infected patients on ART may be caused by the toxicity of 
ARV drugs, especially those with higher CNS penetration. 
ART-related CNS toxicity may be due to direct ARV drug 
CNS toxicity and/or CNS immunopathology related to 
immune restoration in the presence of ART.60 Efforts have 
been made to classify ARV drugs according to their ability 
to penetrate the CNS. In 2008, Letendre et al devised and 
validated a method to quantify the penetration of ARVs into 
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the CNS by giving each ARV drug a CNS penetration effec-
tiveness (CPE) score.61 Currently available information about 
ARV drug characteristics, measured CSF concentrations, 
and effectiveness in the CNS were used to rank ARV drugs 
relative to one another with regard to their ability to penetrate 
the CNS. The authors revised the CPE ranking in 2010 to 
include ARVs from newer classes of drugs (Table 2).46,61 ARV 
regimens with estimated good CNS penetration are generally 
more effective than regimens with worse CNS penetration in 
controlling CSF viral replication, and may contribute to the 
more significant restoration and preservation of neurocogni-
tive function. Smurzynski et al found that in patients using 
ART regimens containing more than three ARV drugs, the 
use of high versus low CPE scoring regimens was correlated 
with better scores on neurocognitive testing. This relation-
ship, however, was not reported in patients using ART with 
three or less ARV drugs.62
Better CNS-penetrating ART provides better control of 
viral replication within the CNS; however, HIV suppres-
sion below the levels of detection does not guarantee full 
cognitive recovery.46 Interestingly, a study by Marra et al 
suggested that ARV drugs with good CNS penetration were 
associated with worse neurocognitive performance.63 In this 
study, ARV regimens with CPE $ 2, indicating good CNS 
penetration, were compared to regimens with CPE , 2. The 
use of a regimen with CPE $ 2 was significantly associated 
Table 2 CPE scores and selected common CNS adverse events associated with ARV medications (as cited in DHHS guidelines for 
the use of antiretroviral agents in HIV-1-infected adults and adolescents and guidelines for the use of antiretroviral agents in pediatric 
HIV infection)9,11,46
ARV drug CPE score* Headache Dizziness Asthenia Insomnia Depression Other CNS^
Nucleoside (nucleotide) reverse-transcriptase inhibitors
Zidovudine 4 x x x
Abacavir 3 x
Didanosine 2
Emtricitabine 3 x
Lamivudine 2 x
Stavudine 2 x
Tenofovir 1 x x
Nonnucleoside reverse-transcriptase inhibitors
Efavirenz 3 x x x x x
Etravirine 2
Nevirapine 4
Rilpivirine 2 x x x
Protease inhibitors
Atazanavir x x x x
Atazanavir/ritonavir 2
Darunavir x
Darunavir/ritonavir 3
Fosamprenavir 2 x
Fosamprenavir/ritonavir 3
Indinavir 3 x x x
Indinavir/ritonavir 4
Lopinavir/ritonavir‡ 3 x x
Nelfinavir 1 x
Ritonavir 1 x x
Tipranavir† x
Tipranavir/ritonavir 1
Saquinavir 1 x
Saquinavir/ritonavir 1
Entry inhibitors
Enfuvirtide 1
Maraviroc 3 x
Integrase inhibitor
Raltegravir 3 x x x
Notes: ^Other CNS symptoms include somnolence, abnormal dreams, impaired concentration, agitation, psychosis, abnormal thinking, hallucinations, euphoria, seizures; 
†rare cases of intracranial hemorrhage reported in adults; ‡global CNS depression reported in premature infants. into the CNS (4 = highest penetration, 3 = high, 2 = 
intermediate, 1 = low); *larger numbers reflect estimates of better penetration.
Abbreviations: ARV, antiretroviral; CNS, central nervous system; CPE, CNS penetration effectiveness.
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with worse Z-scores on a short-battery neuropsychological 
test despite better control of CSF viral replication with ARV 
regimens with good CSF penetration. The authors concluded 
that ARV regimens with better CSF penetration may not lead 
to improved neurocognitive performance. It is important to 
recognize that the interpretation of study results was limited 
due to the small number of subjects, with only 75 subjects 
participating in the short-battery neuropsychological testing. 
Another study of HIV-infected adults compared the over-
all neurological and neuropsychological effects of ARV 
regimens.64 In this study, by Robertson et al, subjects were 
randomized to three treatment arms: A (lamivudine [3TC], 
AZT, plus EFV), B (FTC, ddI, plus atazanavir [ATV]) and 
C (FTC, TDF, plus EFV). Standardized neurological and 
neuropsychological examinations were administered every 
24 weeks during the study period of 4 years. Each study arm 
was assigned a CPE score according to Letendre’s ranking 
system. The total CPE score for arms A, B, and C, were 9, 
7, and 7, respectively, with a higher score indicating higher 
CNS penetration of the overall ART regimen. The study 
detected no significant differences in neurological and neu-
ropsychological outcomes between the randomized ART 
combinations. Authors concluded that regimens with higher 
CPE scores did not correlate with additional neurological or 
neuropsychological benefit. Overall, however, significant 
improvement in neurological and neuropsychological out-
comes did occur over time after initiation of ART, regardless 
of ARV drug combination.
Although overall rates of treatment-limiting CNS 
adverse events of ART are low, especially with newer ARV 
drugs, cognizance of such events is important, since they 
can directly affect adherence to ART.9 Drug-induced CNS 
adverse reactions attributable to individual ARV drugs can 
result in a spectrum of symptoms, ranging from sleep dis-
turbance to cognitive impairment and psychosis.65 Complex 
drug interactions between ARV drugs could also contribute 
to CNS toxicity.66 Published case reports and clinical studies 
of ARV-associated CNS toxicity most commonly report caus-
ative relationships between neuropsychiatric complications of 
ART and NRTIs (AZT and abacavir [ABC]), NNRTIs (EFV 
and RPV) and several PIs.47
While neuropsychiatric side effects may occur with 
almost all ARV medications, the majority of them are self-
limited and do not result in discontinuation of medication. 
In a study that reviewed reasons for discontinuation of ART, 
adverse events accounted for 24% (n = 84) of reasons for 
discontinuing therapy.67 Of all adverse events (n = 84), CNS 
complaints were cited in significantly smaller proportion 
(10%; n = 8), compared to the gastrointestinal abnormalities 
observed in 44% (n = 37) of patients. Among the CNS com-
plaints, headache, insomnia, and dizziness were responsible 
for 7%, 7%, and 5% of all adverse events, respectively.67
Headache is the most frequently cited adverse event 
for NRTIs such as AZT, abacavir, FTC, 3TC, d4T, and 
TDF for children and adults.9,11 Typically, the headache is 
transient, mild to moderate in severity, and can be treated 
 symptomatically. AZT has also been associated with the side 
effects of insomnia and asthenia.9,11
Headache has also been implicated as a common drug 
toxicity for certain PIs, including ATV, darunavir, fosampre-
navir, indinavir (IDV), lopinavir/ritonavir (LPV/RTV) and 
tipranivir. Additionally, IDV, LPV/RTV, and RTV have been 
associated with asthenia, while ATV and IDV have also been 
associated with dizziness.9,11 As with NRTIs, these side effects 
are often self-limited and only mild to moderate in severity, 
usually not requiring a switch in ART. Notably, tipranivir 
has been linked with rare cases of intracranial hemorrhage 
and should be used cautiously in patients with prior history of 
intracranial lesions or bleeding disorder.9 The propylene glycol 
and alcohol components of the LPV/RTV oral solution may 
also contribute to global CNS depression reported in neonates 
and preterm infants and limits the use of this combination PI 
in premature and young infants to those with postmenstrual 
age of .42 weeks and a postnatal age of .14 days.11 LPV/
RTV-associated CNS depression typically resolves within 
1–5 days of discontinuation of the drug.9,11
Neuropsychiatric side effects of the newer classes of ARV 
medications, such as the entry inhibitor maraviroc, include 
dizziness and postural hypotension, while the integrase 
inhibitor raltegravir has been associated with headaches and 
dizziness.9,11 Table 2 summarizes selected common CNS 
adverse events for ARV drugs as cited by DHHS adult and 
pediatric guidelines for use of ARV agents.9,10
A high incidence of the neuropsychiatric effects, rang-
ing from 40% to 70%, has been reported in association with 
NNRTI EFV.68,69 EFV crosses the blood–brain barrier well, 
and CSF-to-plasma ratios have been found to range between 
0.65% and 1.19%.70 Neuropsychiatric manifestations most 
commonly associated with EFV use include dizziness, 
confusion, lethargy, impaired concentration, amnesia, hal-
lucinations, abnormal dreams, insomnia, sleep disorders, 
depression, and irritability.71,72 The CNS symptoms usually 
appear in the first weeks of therapy and abate within several 
weeks.73–77 While the exact mechanism responsible for these 
neuropsychiatric effects by EFV has not been established, 
some studies suggest that the CNS side effects are related to 
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the higher level of plasma EFV exposure . 4000 ng/mL.78 
Since EFV is the substrate to the CYP450 2B6 metabolic path-
way, the polymorphisms in CYP2B6 (particularly 516 T . G) 
has been reported to increase the EFV plasma exposure and 
the severity of EFV-associated neurotoxicity.79
A second-generation NNRTI RPV has also been associ-
ated with CNS adverse events, including depression, insom-
nia, and headache. From safety and efficacy studies comparing 
RPV and EFV, of 686 subjects on RPV, the most common 
treatment-related adverse events ($grade 2) included dizzi-
ness (1%, n = 7), abnormal dreams/nightmares (1%, n = 4), 
headache (2%, n = 9), and insomnia (2%, n = 12).80 When con-
sidering all grades of RPV-related adverse events, any form 
of neurologic adverse event was reported in 17% (n = 117) 
of the subjects, with 8% (n = 55) complaining of dizziness, 
while any form of psychiatric adverse event was reported in 
15% (n = 102) of subjects, with 8% (n = 56) complaining of 
abnormal dreams/nightmares. The frequency of dizziness 
and abnormal dreams/nightmares for RPV was significantly 
lower than that reported in association with EFV, whereas the 
incidence of depression was similarly low for both groups.
Neuropsychiatric effects of TDF
TFV belongs to the class of ARV drugs with low penetration 
into the CNS. Animal data indicate that TFV is transported 
across the blood–CSF barrier but not the blood–brain bar-
rier, due to physicochemical properties of the drug. Its high 
polarity and low lipid solubility reduce its ability to readily 
undergo passive diffusion to cross the blood–brain barrier.81 
The penetration of TFV into the brain, therefore, relies on 
active transport systems to cross the blood–brain/blood–
CSF barrier. These transporters are responsible for both 
efflux and influx of TFV into the CNS.82 Concentrations of 
TFV in the CSF have been found to be only 5% of plasma 
concentrations.83
With limited penetration into the CNS, TFV is unlikely 
to produce direct adverse effects on the CNS. During phase 
II and III clinical trials, TDF exhibited limited neuropsy-
chiatric effects. In the Gilead Sciences study GS-99-903, 
a double-blind comparative controlled trial designed to 
evaluate the safety of TDF in adults, the most common 
neuropsychiatric adverse reactions attributable to the study 
drug were headache and dizziness.38 Overall, from three large 
controlled clinical trials, the most common TDF-associated 
neuropsychiatric adverse reactions with incidence $ 10% and 
grades 2–4 included headache, depression, and asthenia.29 In 
an equivalency trial designed to assess efficacy and safety of 
TDF, cART consisting of TDF, 3TC, and EFV was  compared 
to a regimen containing d4T, 3TC, and EFV. Overall 
frequency of grade 2–4 neuropsychiatric adverse events 
including asthenia (6%–7%), depression (10%–11%), and 
anxiety (6%) were similar between the two groups throughout 
144 weeks of follow-up. A smaller proportion of patients using 
the TDF/3TC/EFV regimen reported headache (14% versus 
17%), insomnia (5% versus 8%), dizziness (3% versus 6%), 
and peripheral neuropathy (1% versus 5%) compared to 
those taking d4T/3TC/EFV.29,79 In an open-label noninfe-
riority study comparing two ARV regimens TDF/FTC/EFV 
with AZT/3TC/EFV, patients receiving a TDF-containing 
ART reported similar frequency of neuropsychiatric adverse 
events in grades 2–4, such as headache (5%–6%), dizziness 
(7%–8%),insomnia (5%–7%), and depression (7%–9%) as 
those on a regimen without TDF.29,83
A case series described nine episodes of neuropsychiatric 
intolerance occurring early after a switch from an ART regi-
men without TDF to a TDF-containing regimen.84 Moderate 
to severe neuropsychiatric adverse events were noted almost 
immediately after TDF initiation. CNS symptoms included 
nightmare (n = 4), insomnia (n = 3), dizziness (n = 4), tinnitus 
(n = 1), nausea (n = 1), and irritability (n = 1). CNS symptoms 
occurring during the 24 months after initiation of TDF included 
nightmares (n = 4) and insomnia (n = 2). Due to these side 
effects, five out of the nine patients switched ARV regimen 
(discontinuing TDF), and one discontinued ARV therapy 
altogether. CNS symptoms improved in all six who changed or 
discontinued regimens. In the three patients who did not switch 
regimens, one had spontaneous resolution of symptoms within 
2 weeks, and two continued to experience sleeping  disorders. 
The mechanism of the emerging CNS adverse effects after the 
introduction of TDF to an EFV-containing regimen remains 
unclear. It was hypothesized that the neuropsychiatric effects 
may have been the result of an unexplained interaction between 
EFV and TDF that resulted in increased levels of EFV, likely 
causing the neuropsychiatric side effects.84 The possibility of 
PK interaction between TDF and EFV has been questioned, 
especially among patients with polymorphism of CYP2B6 
who are slow EFV metabolizers.85 The study, evaluating 
EFV and TDF exposure, reported similar EFV area under 
the plasma vs time curve concentrations (AUC) among the 
adult patients, except for the significantly higher exposure 
among patients with CYP2B6 polymorphism and patients 
receiving concomitant TFV (n = 5; AUC=353,031 ng*h/mL) 
compared to those not receiving TFV (n = 18; AUC=180,689 
ng*h/mL). Typically, however, the concomitant administra-
tion of TDF and EFV has not been associated with significant 
PK/pharmacodynamic interactions.86
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Conclusion
As the armamentarium of ARV drugs continues to grow, 
understanding the potential benefits and risks of each ARV 
agent is essential in designing the most optimal regimen for 
individual patients. TDF, coformulated in multiple FDCs, is 
widely recommended for treatment and prophylaxis of HIV 
infection due to its potency, safety, tolerability, and conve-
nient dosing. The potency of TDF has been instrumental in 
successfully suppressing viral replication and decreasing 
incidence of severe neuropsychiatric disorders associated with 
advanced HIV infection. The low CNS penetration by TFV 
is likely responsible for the minimal spectrum of neuropsy-
chiatric adverse effects associated with the drug. The same 
low CNS penetration of TFV, however, may limit its ability to 
independently reduce HIV viral load in the CNS, potentially 
contributing to persistent low-level HIV viremia, leading 
to mild neuropsychiatric impairments and/or development 
of drug resistance. Combining TDF with ARV drugs with 
high CNS penetration may be strategically beneficial for the 
long-term management of HIV-infected patients. In patients 
on TDF-containing regimens, early recognition of neuropsy-
chiatric disorders is essential to achieve a high quality of life 
and most beneficial long-term outcome of HIV infection.
More clinical studies evaluating the long-term neuropsy-
chological, neurocognitive, and neurodevelopmental effects 
of ARV regimens, particularly among HIV-infected children 
and elderly patients, are needed. Specifically, future studies 
should evaluate the relationship between particular ARV 
regimen CPE scores, CSF viral replication, and overall 
neurological outcome to allow clinicians to estimate the 
benefits and risks of high CSF penetrating ART. Eventually, 
this research could provide valuable insight for improving 
the selection of ART to ensure most optimal long-term neu-
rological outcomes for HIV-infected patients.
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